Securities – Fraud – Scienter
Where a securities fraud complaint has been filed over the failed commercial rollout of an innovative treatment for Alzheimer’s disease, the complaint must be dismissed because (1) none of the defendants’ 25 allegedly false and misleading statements are actionable under the Private Securities Litigation Reform Act and (2) the facts alleged do not support a
Source: masslawyersweekly.com